Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1977 1
1978 2
1983 1
1984 1
1985 2
1987 1
1990 1
1993 1
1994 1
1995 1
1997 2
1998 2
1999 2
2000 2
2001 1
2003 1
2004 1
2005 1
2006 2
2007 3
2008 2
2009 1
2012 1
2013 1
2014 2
2015 4
2018 2
2019 1
2020 2
2021 2
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Splenic manifestation of leukemia"
Page 1
Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.
Requena G, van den Bosch J, Akuthota P, Kovalszki A, Steinfeld J, Kwon N, Van Dyke MK. Requena G, et al. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2125-2134. doi: 10.1016/j.jaip.2022.03.034. Epub 2022 Apr 22. J Allergy Clin Immunol Pract. 2022. PMID: 35470096 Free article. Review.
OBJECTIVE: To describe disease characteristics, treatment, and outcomes of patients with idiopathic (I-HES), myeloproliferative (M-HES), lymphocytic (L-HES), and chronic eosinophilic leukemia, not otherwise specified (CEL-NOS) among HES case reports and aggregate data wher …
OBJECTIVE: To describe disease characteristics, treatment, and outcomes of patients with idiopathic (I-HES), myeloproliferative (M-HES), lym …
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Myelofibrosis.
Mascarenhas J, Kremyanskaya M, Patriarca A, Palandri F, Devos T, Passamonti F, Rampal RK, Mead AJ, Hobbs G, Scandura JM, Talpaz M, Granacher N, Somervaille TCP, Hoffman R, Wondergem MJ, Salama ME, Colak G, Cui J, Kiladjian JJ, Vannucchi AM, Verstovsek S, Curto-García N, Harrison C, Gupta V. Mascarenhas J, et al. J Clin Oncol. 2023 Nov 10;41(32):4993-5004. doi: 10.1200/JCO.22.01972. Epub 2023 Mar 7. J Clin Oncol. 2023. PMID: 36881782 Free PMC article. Clinical Trial.
PURPOSE: Standard therapy for myelofibrosis comprises Janus kinase inhibitors (JAKis), yet spleen response rates of 30%-40%, high discontinuation rates, and a lack of disease modification highlight an unmet need. ...The primary end point is a spleen volume reduction …
PURPOSE: Standard therapy for myelofibrosis comprises Janus kinase inhibitors (JAKis), yet spleen response rates of 30%-40%, high dis …
Essential thrombocythemia.
Brière JB. Brière JB. Orphanet J Rare Dis. 2007 Jan 8;2:3. doi: 10.1186/1750-1172-2-3. Orphanet J Rare Dis. 2007. PMID: 17210076 Free PMC article. Review.
Thromboses of large arteries represent a major cause of mortality associated with ET or can induce severe neurological, cardiac or peripheral artery manifestations. Acute leukemia or myelodysplasia represent only rare and frequently later-onset events. The molecular …
Thromboses of large arteries represent a major cause of mortality associated with ET or can induce severe neurological, cardiac or periphera …
Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis.
Gupta V, Mascarenhas J, Kremyanskaya M, Rampal RK, Talpaz M, Kiladjian JJ, Vannucchi AM, Verstovsek S, Colak G, Dey D, Harrison C. Gupta V, et al. Blood Adv. 2023 Sep 26;7(18):5421-5432. doi: 10.1182/bloodadvances.2023010628. Blood Adv. 2023. PMID: 37530627 Free PMC article.
Pelabresib (CPI-0610), an oral, small-molecule BET1,2 inhibitor (BETi), in combination with ruxolitinib showed improvements in spleen volume reduction (SVR35) and total symptom score reduction (TSS50) from baseline in the phase 2 MANIFEST study (NCT02158858) in pati …
Pelabresib (CPI-0610), an oral, small-molecule BET1,2 inhibitor (BETi), in combination with ruxolitinib showed improvements in spleen …
Hairy cell leukaemia-variant: Disease features and treatment.
Matutes E, Martínez-Trillos A, Campo E. Matutes E, et al. Best Pract Res Clin Haematol. 2015 Dec;28(4):253-63. doi: 10.1016/j.beha.2015.09.002. Epub 2015 Oct 8. Best Pract Res Clin Haematol. 2015. PMID: 26614904 Review.
Hairy cell leukaemia-variant (HCL-V) is a rare B-cell malignancy that affects elderly males and manifests with splenomegaly, lymphocytosis and cytopenias without monocytopenia. ...The immunophenotype is that of a clonal B-cell CD11c and CD103 positive but, unlike cl …
Hairy cell leukaemia-variant (HCL-V) is a rare B-cell malignancy that affects elderly males and manifests with splenomegaly, l …
New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis.
Rammaert B, Desjardins A, Lortholary O. Rammaert B, et al. Mycoses. 2012 May;55(3):e74-84. doi: 10.1111/j.1439-0507.2012.02182.x. Epub 2012 Feb 24. Mycoses. 2012. PMID: 22360318 Review.
The incidence of HSC ranges from 3% to 29% in patients suffering from Acute Leukaemia. However, it is now seen less frequently with the widespread use of antifungal agents as prophylaxis or as preemptive therapy. ...In this context, new therapeutic approaches such as the u …
The incidence of HSC ranges from 3% to 29% in patients suffering from Acute Leukaemia. However, it is now seen less frequently with t …
Hairy cell leukemia: current concepts.
Cannon T, Mobarek D, Wegge J, Tabbara IA. Cannon T, et al. Cancer Invest. 2008 Oct;26(8):860-5. doi: 10.1080/07357900801965034. Cancer Invest. 2008. PMID: 18798068 Review.
Hairy cell Leukemia (HCL) is a chronic lymphoproliferative disorder that was characterized in the late 1950s. ...Other clinical manifestations include recurrent opportunistic infections and vasculitis. ...
Hairy cell Leukemia (HCL) is a chronic lymphoproliferative disorder that was characterized in the late 1950s. ...Other clinical …
Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis.
Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Kontoyiannis DP, et al. Infect Dis Clin North Am. 2000 Sep;14(3):721-39. doi: 10.1016/s0891-5520(05)70128-8. Infect Dis Clin North Am. 2000. PMID: 10987117 Review.
Much progress has been made over the last decade in diagnosing and treating CDC, a chronic and debilitating infection that interferes with the delivery of intensive cytotoxic chemotherapy in patients with leukemia. The use of fluconazole prophylaxis in these patients has d …
Much progress has been made over the last decade in diagnosing and treating CDC, a chronic and debilitating infection that interferes with t …
Hepatitis C virus and lymphoma.
Viswanatha DS, Dogan A. Viswanatha DS, et al. J Clin Pathol. 2007 Dec;60(12):1378-83. doi: 10.1136/jcp.2007.051870. J Clin Pathol. 2007. PMID: 18042694 Free PMC article. Review.
On the strength of epidemiological data, emerging biological investigations and clinical observations, HCV appears to be involved in the pathogenesis of at least a proportion of patients with NHL. Morphologically, HCV-associated lymphomas represent a variety of histologica …
On the strength of epidemiological data, emerging biological investigations and clinical observations, HCV appears to be involved in …
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients.
Ishii K, Pouzolles M, Chien CD, Erwin-Cohen RA, Kohler ME, Qin H, Lei H, Kuhn S, Ombrello AK, Dulau-Florea A, Eckhaus MA, Shalabi H, Yates B, Lichtenstein DA, Zimmermann VS, Kondo T, Shern JF, Young HA, Taylor N, Shah NN, Fry TJ. Ishii K, et al. J Clin Invest. 2020 Oct 1;130(10):5425-5443. doi: 10.1172/JCI130059. J Clin Invest. 2020. PMID: 32925169 Free PMC article.
Following in vivo clearance of leukemia, perforin-deficient CAR T cells reexpanded, resulting in splenomegaly with disruption of normal splenic architecture and the presence of hemophagocytes, which are findings reminiscent of HLH. Notably, a substantial fraction of …
Following in vivo clearance of leukemia, perforin-deficient CAR T cells reexpanded, resulting in splenomegaly with disruption of norm …
50 results